Celularity, inc.

Celularity, Inc. is a clinical-stage biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for various indications across cancer, immunologic, infectious, and degenerative diseases. The company's innovative approach to cell therapy involves using genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs) derived from the placenta.

The use of placental-derived allogeneic cell therapies has several advantages over traditional autologous cell therapies. For one thing, it eliminates the need for donors to undergo invasive procedures to harvest their own cells. Additionally, it allows for the creation of a standardized product that can be manufactured at scale and stored for future use.

Celularity's proprietary platform technology enables the isolation and expansion of multiple types of placental-derived stem cells with unique properties that make them ideal candidates for therapeutic applications. These stem cells have been shown to possess potent immunomodulatory properties that can help regulate immune responses in patients with autoimmune disorders or those undergoing organ transplantation.

One area where Celularity is making significant strides is in the development of CAR-T cell therapies. CAR-T (Chimeric Antigen Receptor T-cell) therapy involves engineering a patient's own T-cells to recognize and attack cancerous tumors. However, this approach has several limitations such as high cost and time-consuming manufacturing processes.

Celularity's off-the-shelf CAR-T products offer a more cost-effective alternative by using donor-derived T-cells that have been genetically modified to target specific tumor antigens. This approach not only reduces costs but also allows for faster production times compared to traditional autologous CAR-T products.

Another promising area where Celularity is focusing its efforts is on developing NK (Natural Killer) cell-based therapies for cancer treatment. NK cells are part of our innate immune system and play an important role in recognizing and killing infected or abnormal cells such as cancerous tumors.

Celularity's proprietary technology enables the isolation and expansion of large quantities of functional NK cells from placental tissue which can then be used as an off-the-shelf product for cancer treatment without requiring HLA matching between donor and recipient.

In addition to its work on cellular therapeutics, Celularity also has ongoing research programs focused on developing exosomes-based therapeutics derived from placental tissue which have shown promise in preclinical studies as potential treatments for various diseases including neurodegenerative disorders like Alzheimer’s disease.

Overall Celularity’s innovative approach towards developing off-the-shelf allogeneic cellular therapeutics holds great promise towards revolutionizing modern medicine by providing safe effective treatments at affordable prices while reducing manufacturing timescales significantly compared with current methods used today making them one step closer towards achieving their mission statement “To extend life through science”.